Drug Trial Radar · NCT04318938
Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping
Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
118
Actual
Start
Mar 30, 2020
Primary completion
May 30, 2026
Study completion May 30, 2026
Sponsor
- Lead sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Thoraxklinik-Heidelberg gGmbH; Takeda
- First posted
- Mar 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, randomized, open-label, multicenter phase II study investigating the advancing Brigatinib properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotyping
Conditions
- NSCLC
Interventions
BrigatinibDrug
Treatment with Brigatinib
Tyrosine kinase inhibitorDrug
Treatment with any TKI
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) of 1st-line treatment according to RECIST v1.1Time frame: 68 months
Locations
26 sites in 1 country. Site status is shown where the registry gives one.
HELIOS Klinikum Emil von Behring
Berlin, Germany
Charité Berlin
Berlin, Germany
Lungenklinik Köln - Merheim
Cologne, Germany
Universitätsmedizin Essen
Essen, Germany
Klinikum Esslingen
Esslingen am Neckar, Germany
Krankenhaus Nordwest Frankfurt
Frankfurt am Main, Germany
Universitätsklinikum Freiburg
Freiburg im Breisgau, Germany
Niels-Stensen-Kliniken Georgsmarienhütte
Georgsmarienhütte, Germany
Universitätsklinikum Gießen
Giessen, Germany
Studiengesellschaft Hämato-Onkologie Hamburg
Hamburg, Germany
Evangelisches Krankenhaus Hamm
Hamm, Germany
KRH Klinikum Siloah Hannover
Hanover, Germany
Medizinische Hochschule Hannover
Hanover, Germany
Thoraxklinik am Universitätsklinikum Heidelberg
Heidelberg, Germany
Lungenklinik Hemer
Hemer, Germany
Universitätsklinikum Jena
Jena, Germany
Universitätsklinikum Leipzig
Leipzig, Germany
Universitätsmedizin Mainz
Mainz, Germany
Klinik der LMU München - Innenstadt
München, Germany
Universitätsklinikum Münster
Münster, Germany
Klinikum Nürnberg
Nuremberg, Germany
Pius Hospital Oldenburg
Oldenburg, Germany
Universitätsklinikum Regensburg
Regensburg, Germany
Klinik Schillerhöhe
Stuttgart, Germany
Universitätsklinikum Ulm
Ulm, Germany
Universitätsklinikum Würzburg
Würzburg, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.